Next Generation Drugs in Kidney Cancer

 

The aim of this evaluation form is to gain your feedback, in order to maintain high educational standards and provide a reference for continuous improvement. Please indicate which rating reflects your answer.

Questions marked with are required.

1. Did this E-Learning module allow you to put into clinical perspective data from recent clinical trials with targeted therapies in patients with advanced renal cell cancer? (1: no, not at all; 5: yes, absolutely)

2. Did this E-Learning module allow you to put into clinical perspective data from recent clinical trials with checkpoint inhibitors in patients with advanced renal cell cancer? (1: no, not at all; 5: yes, absolutely)

3. Did this E-Learning module allow you to elaborate therapeutic approaches that are currently being examined in the clinical trial setting among renal cell cancer patients with potential to enter clinical practice in the future? (1: no, not at all; 5: yes, absolutely)

4. Please, provide your overall rating of the quality of the education offered by this E-Learning module. (1-poor; 5-excellent)

5. How would you rate the interactivity level offered in the E-Learning material? (1-poor; 5-excellent)

6. Was the information useful and relevant to your work and practice? (1-not at all; 5-absolutely)

7. Do you feel that the information presented was well balanced and supported by adequate evidence? (1-not at all; 5-absolutely)

8. Do you think that the scientific content of this E-learning activity contains any commercial material?

9. If you answered YES, please motivate your choice in the box below:

10. If you would like to add your personal comments or make suggestion to improve future ESMO E-Learning material, please write in the box below: